|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007131,
umls-concept:C0008976,
umls-concept:C0034656,
umls-concept:C0079083,
umls-concept:C0144576,
umls-concept:C0205179,
umls-concept:C0376690,
umls-concept:C0679729,
umls-concept:C0684249,
umls-concept:C1319266,
umls-concept:C1518578
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2000-12-26
|
|
pubmed:abstractText |
The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present prospective study was to evaluate the dose response relationship of paclitaxel.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:DimopoulosMM,
pubmed-author:FountzilasGG,
pubmed-author:KalophonosCC,
pubmed-author:KosmidisPP,
pubmed-author:MylonakisNN,
pubmed-author:NikolaidisCC,
pubmed-author:PapaconstantinouCC,
pubmed-author:PapadimitriouCC,
pubmed-author:PavlidisNN,
pubmed-author:SamantasEE,
pubmed-author:SkarlosDD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
799-805
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10997806-Adult,
pubmed-meshheading:10997806-Aged,
pubmed-meshheading:10997806-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10997806-Area Under Curve,
pubmed-meshheading:10997806-Carboplatin,
pubmed-meshheading:10997806-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10997806-Disease Progression,
pubmed-meshheading:10997806-Dose-Response Relationship, Drug,
pubmed-meshheading:10997806-Drug Administration Schedule,
pubmed-meshheading:10997806-Female,
pubmed-meshheading:10997806-Humans,
pubmed-meshheading:10997806-Leukopenia,
pubmed-meshheading:10997806-Lung Neoplasms,
pubmed-meshheading:10997806-Male,
pubmed-meshheading:10997806-Middle Aged,
pubmed-meshheading:10997806-Nervous System Diseases,
pubmed-meshheading:10997806-Paclitaxel,
pubmed-meshheading:10997806-Prognosis,
pubmed-meshheading:10997806-Survival Analysis,
pubmed-meshheading:10997806-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).
|
|
pubmed:affiliation |
Hygeia Hospital, Athens, Greece. parkosmi@otenet.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
